[Federal Register Volume 82, Number 205 (Wednesday, October 25, 2017)]
[Notices]
[Pages 49388-49389]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-23128]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute on Drug Abuse; Notice of Closed Meetings
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended, notice is hereby given of the following meetings.
The meetings will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Institute on Drug Abuse Special
Emphasis Panel; Multi-
[[Page 49389]]
Site Studies for System-Level Implementation of Substance Use
Prevention and Treatment Services (R01; R34).
Date: November 7, 2017.
Time: 1:00 p.m. to 3:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Neuroscience Center, 6001
Executive Boulevard, Rockville, MD 20852 (Telephone Conference
Call).
Contact Person: Gerald L. McLaughlin, Ph.D., Scientific Review
Officer, Office of Extramural Policy and Review, National Institute
on Drug Abuse, NIH, DHHS, 6001 Executive Blvd., Room 4238, MSC 9550,
Bethesda, MD 20892-9550, 301-827-5819, [email protected].
Name of Committee: National Institute on Drug Abuse Special
Emphasis Panel; Limited Competition--Cohort Studies of HIV/AIDS and
Substance Abuse (U01).
Date: November 7, 2017.
Time: 2:00 p.m. to 3:30 p.m.
Agenda: To review and evaluate cooperative agreement
applications.
Place: National Institutes of Health, Neuroscience Center, 6001
Executive Boulevard, Rockville, MD 20852 (Telephone Conference
Call).
Contact Person: Hiromi Ono, Ph.D., Scientific Review Officer,
Office of Extramural Policy and Review, National Institute on Drug
Abuse, National Institutes of Health, DHHS, 6001 Executive
Boulevard, Room 4238, MSC 9550, Bethesda, MD 20892, 301-827-5820,
[email protected].
Name of Committee: National Institute on Drug Abuse Special
Emphasis Panel; Advancing Exceptional Research on HIV/AIDS and
Substance Abuse (R01).
Date: November 10, 2017.
Time: 12:00 p.m. to 3:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Neuroscience Center, 6001
Executive Boulevard, Rockville, MD 20852 (Telephone Conference
Call).
Contact Person: Hiromi Ono, Ph.D., Scientific Review Officer,
Office of Extramural Policy and Review, National Institute on Drug
Abuse, National Institutes of Health, DHHS, 6001 Executive
Boulevard, Room 4238, MSC 9550, Bethesda, MD 20892, 301-827-5820,
[email protected].
Name of Committee: National Institute on Drug Abuse Special
Emphasis Panel; Wearable to Track Recovery and Relapse Factors for
People w/Addiction (R43, R44).
Date: November 21, 2017.
Time: 1:00 p.m. to 4:30 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Neuroscience Center, 6001
Executive Boulevard, Rockville, MD 20852 (Telephone Conference
Call).
Contact Person: Julia Berzhanskaya, Ph.D., Scientific Review
Officer, Office of Extramural Policy and Review, Division of
Extramural Research, National Institute on Drug Abuse, NIH, DHHS,
6001 Executive Boulevard, Room 4234, MSC 9550, Bethesda, MD 20892,
301-827-5840, [email protected].
Name of Committee: National Institute on Drug Abuse Special
Emphasis Panel; NIDA Research Education Program for Clinical
Researchers and Clinicians (R25).
Date: December 4, 2017.
Time: 12:00 p.m. to 3:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Neuroscience Center, 6001
Executive Boulevard, Rockville, MD 20852 (Telephone Conference
Call).
Contact Person: Gerald L. McLaughlin, Ph.D., Scientific Review
Officer, Office of Extramural Policy and Review, National Institute
on Drug Abuse, NIH, DHHS, 6001 Executive Blvd., Room 4238, MSC 9550,
Bethesda, MD 20892-9550, 301-827-5819, [email protected].
Name of Committee: National Institute on Drug Abuse Special
Emphasis Panel; Nasal Delivery of CNS Therapeutics (R41, R42, R43,
R44).
Date: December 5, 2017.
Time: 1:00 p.m. to 4:30 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Neuroscience Center, 6001
Executive Boulevard, Rockville, MD 20852 (Telephone Conference
Call).
Contact Person: Julia Berzhanskaya, Ph.D., Scientific Review
Officer, Office of Extramural Policy and Review, Division of
Extramural Research, National Institute on Drug Abuse, NIH, DHHS,
6001 Executive Boulevard, Room 4234, MSC 9550, Bethesda, MD 20892,
301-827-5840, [email protected].
Name of Committee: National Institute on Drug Abuse Special
Emphasis Panel; Conference Grant Review (R13).
Date: December 6, 2017.
Time: 1:00 p.m. to 4:30 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Neuroscience Center, 6001
Executive Boulevard, Rockville, MD 20852 (Telephone Conference
Call).
Contact Person: Shang-Yi Anne Tsai, Ph.D., Scientific Review
Officer, Office of Extramural Policy and Review, Division of
Extramural Research, National Institute on Drug Abuse, NIH, DHHS,
6001 Executive Boulevard, Room 4228, MSC 9550, Bethesda, MD 20892,
301-827-5842, [email protected].
(Catalogue of Federal Domestic Assistance Program Nos.: 93.279, Drug
Abuse and Addiction Research Programs, National Institutes of
Health, HHS)
Dated: October 19, 2017.
Natasha M. Copeland,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2017-23128 Filed 10-24-17; 8:45 am]
BILLING CODE 4140-01-P